Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Mo Qatanani Sells 1,936 Shares

Scholar Rock Holding Co. (NASDAQ:SRRK) insider Mo Qatanani sold 1,936 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $8.58, for a total transaction of $16,610.88. Following the transaction, the insider now directly owns 142,768 shares of the company’s stock, valued at $1,224,949.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Scholar Rock Price Performance

SRRK opened at $9.39 on Friday. The firm has a 50-day moving average price of $8.93 and a 200-day moving average price of $11.26. The company has a quick ratio of 6.04, a current ratio of 6.04 and a debt-to-equity ratio of 0.36. Scholar Rock Holding Co. has a twelve month low of $6.03 and a twelve month high of $21.17. The company has a market capitalization of $751.48 million, a price-to-earnings ratio of -4.49 and a beta of 0.82.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.01. During the same quarter in the prior year, the firm earned ($0.47) earnings per share. Equities analysts expect that Scholar Rock Holding Co. will post -2.39 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on SRRK. BMO Capital Markets lifted their target price on shares of Scholar Rock from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Scholar Rock in a report on Tuesday, June 25th. Finally, Wedbush reissued an “outperform” rating and set a $23.00 price objective on shares of Scholar Rock in a report on Thursday, August 8th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $26.43.

Hedge Funds Weigh In On Scholar Rock

A number of large investors have recently bought and sold shares of SRRK. Amalgamated Bank lifted its holdings in Scholar Rock by 15.5% in the 4th quarter. Amalgamated Bank now owns 4,869 shares of the company’s stock worth $92,000 after buying an additional 652 shares during the period. Walleye Trading LLC purchased a new stake in shares of Scholar Rock during the first quarter valued at $178,000. Principal Financial Group Inc. bought a new position in Scholar Rock during the second quarter valued at approximately $98,000. Hsbc Holdings PLC bought a new stake in shares of Scholar Rock during the 2nd quarter valued at about $100,000. Finally, Point72 DIFC Ltd bought a new position in shares of Scholar Rock in the second quarter worth about $103,000. 91.08% of the stock is owned by hedge funds and other institutional investors.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.